Application of human chorionic gonadotropin in preparation of pregnancy assisting medicine for patients with premature ovarian insufficiency

A technology for chorionic gonadotropin and ovarian function, which can be used in drug combinations, sexual diseases, pharmaceutical formulations, etc., and can solve the problems of unclear etiology, uncertain treatment effect, and high cost of POI.

Pending Publication Date: 2021-10-01
THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, nearly 50% of POIs have unknown etiology
Donating eggs is currently the most effective treatment, but patients cannot obtain offspring with their own genes
[0003] There are some methods of in vitro activation of dormant follicles in patients with POI, such as autologous transplantation after primordial follicle activation (IVA), ovarian injection of platelet-rich plasma (PRP) or stem cells, ovarian transplantation or mitochondrial replacement therapy, etc., which are expensive and the treatment effect is uncertain
At present, there is no research report on the activation of dormant follicles in vivo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human chorionic gonadotropin in preparation of pregnancy assisting medicine for patients with premature ovarian insufficiency
  • Application of human chorionic gonadotropin in preparation of pregnancy assisting medicine for patients with premature ovarian insufficiency
  • Application of human chorionic gonadotropin in preparation of pregnancy assisting medicine for patients with premature ovarian insufficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] A fertility aid drug for patients with premature ovarian insufficiency, the drug is composed of the following independently packaged preparations: progamma, medroxyprogesterone tablets and human chorionic gonadotropin.

Embodiment 2

[0032] Fu Mou, 31 years old, 0-0-0-0, has not been pregnant for 1 year without contraception. Since the age of 23, she began to have thin menstruation, with a menstrual cycle of 40 to 180 days, accompanied by symptoms such as hot flashes, insomnia, and dyspareunia. She has been interrupting hormone replacement therapy to maintain normal menstruation. On April 20, 2017, the endocrine test in the other hospital: FSH 95.65mIU / ml, E212 pg / ml, LH 29.75mIU / ml. After getting married in March 2018, I started to prepare for pregnancy. I took femotone orally every month to maintain menstruation, and B-ultrasound monitored follicles every week or every two weeks. B-ultrasound for 1 year showed that both ovaries were atrophic and there were no follicles.

[0033] First visit on June 11, 2019. B-ultrasound on the day of the first visit: the size of the uterus was 38*42*40mm, and the echo of the muscular layer was uniform; the left ovary was 12*7mm, the ovary was solid, and no follicles we...

Embodiment 3

[0036] Lu, 31 years old, 1-0-0-1, has not been pregnant for 7 years without contraception. The patient gave birth to a child with her current husband 7 years ago, and has not been pregnant since then without contraception. At the age of 26, the menstrual cycle was advanced, and the menstrual cycle was disordered in the past 2 years. He needed to withdraw progesterone and bleed. One year ago, he began to have hot flashes and insomnia symptoms, and he took femotone intermittently to maintain menstruation. No antral follicles were found in continuous B-ultrasound monitoring for 1 year. In April 2019, bFSH was 32.26mIU / ml; in July 2019, bFSH was 52.67mIU / ml; in April 2020, FSH was 64.83mIU / ml, and AMH was 0.01ng / ml.

[0037] First visit on May 15, 2020. The B-ultrasound on the day of the first visit revealed bilateral ovarian atrophy (Lov 12*9; Rov 12*10), with solid echoes and no follicles in both ovaries. Karyotype 46, XX. FSH 36.36mIU / ml, E2105 pg / ml, LH 22.23mIU / ml.

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of pharmacy, in particular to application of human chorionic gonadotropin in preparation of a pregnancy assisting medicine for patients with premature ovarian insufficiency. According to the medicine prepared from the human chorionic gonadotropin, the FSH of a patient is reduced to be smaller than 15 mIU / ml, the LH of the patient is reduced to be smaller than 10 mIU / ml, then 10000U of HCG is injected into the muscle of the patient at a time, dormant follicles can be activated in vivo, and therefore POI patients can obtain offspring with genetic genes of the POI patients, and the medicine has the advantages of being economical, convenient and free of pain.

Description

technical field [0001] The invention relates to the technical field of pharmacy, in particular to the application of human chorionic gonadotropin in the preparation of fertility aids for patients with premature ovarian insufficiency. Background technique [0002] Premature ovarian insufficiency (POI) refers to the clinical syndrome of ovarian activity decline in women before the age of 40. feature. The characteristics of POI patients: ovarian follicle depletion, lack of growing follicles, few remaining dormant follicles (<1000), and conventional ovulation induction drugs are ineffective. The etiology of POI is mainly sex chromosome and autosomal gene defects, autoimmune dysfunction, infection or iatrogenic factors can all lead to POI. However, the cause of POI is unknown in nearly 50% of cases. Donating eggs is currently the most effective treatment, but patients cannot obtain offspring with their own genes. [0003] There are some methods of in vitro activation of do...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/24A61K31/565A61K31/57A61P15/08
CPCA61K38/24A61K31/565A61K31/57A61P15/08A61K2300/00
Inventor 陈晓徐键喻员员胡瑛瑛李游江
Owner THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap